The results will be presented on May 24 as an oral presentation at the Mini Symposium "Looking for the Crystal Ball: Biomarkers to Predict Disease Progression and Mortality in ILD" at the American Thoracic Society 2023 International Conference (ATS 2023) in Washington, DC.
Interstitial lung diseases are a group of lung diseases characterized by progressive scarring of lung tissue that causes progressive difficulty in breathing and early death, particularly if untreated.
Standard diagnosis is done with CT scan along with lung function testing, which is evaluated through measuring lung volumes. However, risky, invasive and costly procedures, such as lung biopsy, can be required for specific diagnosis and prognostication.
Therefore, a low-cost, widely-accessible software tool to help clinicians diagnose, risk assess, and subsequently treat patients could potentially be the difference between improved prognosis or significant disability.
Imvaria's Fibresolve is being developed to serve as adjunct in assessment of ILD, including idiopathic pulmonary fibrosis, potentially avoiding expensive, invasive surgical testing. Fibresolve uses AI to analyze CT imaging for specific, novel patterns.
The software has Breakthrough Devices Designation from the Food and Drug Administration and is currently for investigational-use only.
In the study presented at ATS 2023 titled "Chest Computed Tomography Machine Learning Classifier for Idiopathic Pulmonary Fibrosis Predicts Mortality in Interstitial Lung Diseases," researchers from Imvaria and its collaborators assessed Fibresolve in 228 patients with IPF and other ILD, adjusting for Gender, Age, and Physiology score (including forced vital capacity or FVC).
In all models tested, Fibresolve significantly predicted the risk of death in ILD patients.
The company also announced three additional poster presentations at ATS 2023 demonstrating the development and utility of Fibresolve.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review